纳米技术用于中药治疗非小细胞肺癌的应用前景探讨

Nanotechnology-assisted traditional Chinese medicine for non-small cell lung cancer: advances and prospects

摘要

非小细胞肺癌(non-small cell lung cancer,NSCLC)的发病率和死亡率位居全球恶性肿瘤前列。目前,NSCLC患者的管理在临床实践中面临重大挑战,其术后并发症死亡率较高,且药物不良反应较大。近年来,纳米医学方法通过提供高效的药物纳米递送系统,精准地将抗肿瘤药物递送到肿瘤细胞中,突破传统化疗的局限性,增强NSCLC的疗效。此外,中医药在NSCLC防治中优势显著,多种中药单体、活性成分与其复方通过“多成分-多靶点-多途径”增强免疫力、提高生活质量以及降低NSCLC转移风险,但其存在水溶解性差、生物利用度低与靶向性不足等问题。纳米递送系统通过提高中药活性成分的生物利用度和溶解度,同时精准靶向肿瘤细胞,可高效、精准地治疗NSCLC。本文基于纳米递送系统综述中药-纳米协同治疗NSCLC的研究进展,探讨其应用前景,旨在为NSCLC治疗开拓新的方法与思路。

Abstract

The incidence and mortality rate of non-small cell lung cancer (NSCLC) rank among the highest among malignant tumors globally. Currently, the management of NSCLC patients poses significant challenges in clinical practice, characterized by high postoperative complication mortality rates and substantial side effects from drug therapy. In recent years, nanomedicine approaches have emerged by providing efficient nano-drug delivery systems that precisely deliver anticancer drugs to cancer cells, overcoming the limitations of traditional chemotherapy to enhance NSCLC treatment efficacy. Furthermore, traditional Chinese medicine (TCM) demonstrates remarkable advantages in the prevention and treatment of NSCLC. Various TCM monomers, active components, and compound formulations enhance immunity, improve quality of life, and reduce NSCLC metastasis risk through multi-component, multi-target, and multi-pathway mechanisms. However, they face challenges such as poor water solubility, low bioavailability, and insufficient targeting specificity. Nano-delivery systems address these issues by enhancing the bioavailability and solubility of active TCM components while enabling precise targeting of cancer cells for efficient and accurate NSCLC treatment. Therefore, this article reviews the research progress in the synergistic treatment of NSCLC using TCM-nano strategies based on nano-delivery systems, while exploring their application prospects, aiming to develop new methods and approaches for NSCLC therapy.    

关键词

纳米递送系统 / 非小细胞肺癌 / 中药-纳米 / 研究进展 / 应用前景

Key words

nano-delivery system / non-small cell lung cancer / traditional Chinese medicine-nano / research progress / application prospect

[1] WANG YY, FU M, LIU JJ, et al. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer[J]. Int J Nanomedicine, 2019, 14: 4071-4090.
[2] WONG MCS, LAO XQ, HO KF, et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status[J]. Sci Rep, 2017, 7(1): 14300.
[3] BUNN PA Jr, SORIANO A, JOHNSON G, et al. New therapeutic strategies for lung cancer: biology and molecular biology come of age[J]. Chest, 2000, 117(4 Suppl 1): 163S-168S.
[4] KROEP JR, GIACCONE G, TOLIS C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines[J]. Br J Cancer, 2000, 83(8): 1069-1076.
[5] PANZARINI E, DINI L. Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?[J]. Mol Pharm, 2014, 11(8): 2527-2538.
[6] XU LM, LIU J, XI JB, et al. Synergized multimodal therapy for safe and effective reversal of cancer multidrug resistance based on low-level photothermal and photodynamic effects[J]. Small, 2018: e1800785.
[7] MI Y, SHAO ZY, VANG J, et al. Application of nanotechnology to cancer radiotherapy[J]. Cancer Nanotechnol, 2016, 7(1): 11.
[8] SHIM G, KIM MG, KIM D, et al. Nanoformulation-based sequential combination cancer therapy[J]. Adv Drug Deliv Rev, 2017, 115: 57-81.
[9] VITORINO C, ALMEIDA J, GONÇALVES LM, et al. Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail[J]. J Control Release, 2013, 167(3): 301-314.
[10] BELOQUI A, SOLINÍS MÁ, RODRÍGUEZ-GASCÓN A, et al. Nanostructured lipid carriers: Promising drug delivery systems for future clinics[J]. Nanomedicine, 2016, 12(1): 143-161.
[11] LI X, JIA XQ, NIU H. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy[J]. Int J Nanomedicine, 2018, 13: 4107-4119.
[12] PENG LH, WANG MZ, CHU Y, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma[J]. Sci Adv, 2020, 6(27): eaba2735.
[13] XIAO QY, TAN MH, YAN G, et al. Revolutionizing lung cancer treatment: harnessing exosomes as early diagnostic biomarkers, therapeutics and nano-delivery platforms[J]. J Nanobiotechnology, 2025, 23(1): 232.
[14] 文世豪, 王文萍, 方熙茹. 中医药治疗非小细胞肺癌热点及研究态势[J]. 中医肿瘤学杂志, 2024, 6(6): 104-112.
[15] KONG FM, WANG CR, ZHAO LL, et al. Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms[J]. Chin Herb Med, 2023, 15(4): 509-515.
[16] 吕春艳, 韩锐, 崔闻宇, 等. 基于中药单体构建的环境响应型纳米递药系统在肿瘤治疗中的研究进展[J]. 医药导报, 2024, 43(11): 1799-1804.
[17] VENTOLA CL. Progress in nanomedicine: approved and investigational nanodrugs[J]. P T, 2017, 42(12): 742-755.
[18] GANDHI S, ROY I. Lipid-based inhalable micro- and nanocarriers of active agents for treating non-small-cell lung cancer[J]. Pharmaceutics, 2023, 15(5): 1457.
[19] REDRUELLO-GUERRERO P, CÓRDOBA-PELÁEZ P, LÁINEZ-RAMOS-BOSSINI AJ, et al. Liposomal doxorubicin In vitro and In vivo assays in non-small cell lung cancer: a systematic review[J]. Curr Drug Deliv, 2024, 21(10): 1346-1361.
[20] KOSHKINA NV, WALDREP JC, ROBERTS LE, et al. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model[J]. Clin Cancer Res, 2001, 7(10): 3258-3262.
[21] LI F, WANG Y, CHEN WL, et al. Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment[J]. Theranostics, 2019, 9(20): 5886-5898.
[22] PARK YI, KWON SH, LEE G, et al. pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small cell lung cancer[J]. J Control Release, 2021, 330: 1-14.
[23] UTI DE, ALUM EU, ATANGWHO IJ, et al. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics[J]. J Nanobiotechnol, 2025, 23(1): 336.
[24] XIONG K, ZHANG Y, WEN Q, et al. Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy[J]. Int J Pharm, 2020, 589: 119875.
[25] LI C, ZHANG J, ZU YJ, et al. Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals[J]. Chin J Nat Med, 2015, 13(9): 641-652.
[26] WANG S, SU R, NIE SF, et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals[J]. J Nutr Biochem, 2014, 25(4): 363-376.
[27] LIU FF, HOWARD CB, PIE HD, et al. Immune-modulating nanomedicines for enhanced drug delivery to non-small-cell lung cancer[J]. Biomaterials, 2025, 317: 123089.
[28] LE ND, NGUYEN BL, PATIL BR, et al. Antiangiogenic therapeutic mRNA delivery using lung-selective polymeric nanomedicine for lung cancer treatment[J]. ACS Nano, 2024, 18(11): 8392-8410.
[29] HUANG JX, ZHUANG C, CHEN J, et al. Targeted drug/gene/photodynamic therapy via a stimuli-responsive dendritic-polymer-based nanococktail for treatment of EGFR-TKI-resistant non-small-cell lung cancer[J]. Adv Mater, 2022, 34(27): e2201516.
[30] SHI M, GU A, TU H, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial[J]. Ann Oncol, 2021, 32(1): 85-96.
[31] YADAV P, AMBUDKAR SV, PRASAD NR. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer[J]. J Nanobiotechnology, 2022, 20(1): 423.
[32] GONG FR, WANG RR, ZHU ZQ, et al. Drug-interactive mPEG- b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel[J]. Drug Deliv, 2020, 27(1): 238-247.
[33] WANG CE, STAYTON PS, PUN SH, et al. Polymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug delivery[J]. J Control Release, 2015, 219: 345-354.
[34] HAN XX, CHEN D, SUN J, et al. A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time[J]. J Biomater Sci Polym Ed, 2016, 27(7): 626-642.
[35] BLANCO E, BEY EA, KHEMTONG C, et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy[J]. Cancer Res, 2010, 70(10): 3896-3904.
[36] ERKISA M, ARI F, BÜYÜKKRÖGLU G, et al. Preparation and characterization of palladium derivate-loaded micelle formulation in vitro as an innovative therapy option against non-small cell lung cancer cells[J]. Chem Biodivers, 2021, 18(9): e2100402.
[37] LU J, LOU YQ, ZHANG YW, et al. Paclitaxel has a reduced toxicity profile in healthy rats after polymeric micellar nanoparticle delivery[J]. Int J Nanomedicine, 2023, 18: 263-276.
[38] FANG RH, GAO WW, ZHANG LF. Targeting drugs to tumours using cell membrane-coated nanoparticles[J]. Nat Rev Clin Oncol, 2023, 20(1): 33-48.
[39] YAN QH, GONG L, TAN ZH, et al. Targeting tumor microenvironment with biomimetic nanovesicles for non-small cell lung cancer gene therapy[J]. J Nanobiotechnology, 2025, 23(1): 624.
[40] CRYER AM, CHAN C, EFTYCHIDOU A, et al. Tyrosine kinase inhibitor gold nanoconjugates for the treatment of non-small cell lung cancer[J]. ACS Appl Mater Interfaces, 2019, 11(18): 16336-16346.
[41] ZHU ZT, LV ZZ, FAN YR, et al. A neovascularization and EGFR dual-targeting gold nanotheranostic system for non-small cell lung cancer treatment[J]. Adv Healthc Mater, 2025, 14(21): e2500854.
[42] SINGH Y, MEHER JG, RAVAL K, et al. Nanoemulsion: Concepts, development and applications in drug delivery[J]. J Control Release, 2017, 252: 28-49.
[43] RAMOS DOCAMPO E, GARCÍA-FERNÁNDEZ J, MÁRMOL I, et al. Mechanistic insights into sphingomyelin nanoemulsions as drug delivery systems for non-small cell lung cancer therapy[J]. Pharmaceutics, 2025, 17(4): 461.
[44] YANG J, LI YB, SUN JM, et al. An osimertinib-perfluorocarbon nanoemulsion with excellent targeted therapeutic efficacy in non-small cell lung cancer: achieving intratracheal and intravenous administration[J]. ACS Nano, 2022, 16(8): 12590-12605.
[45] 安鹏航, 唐铮芳, 魏征, 等. 中医药干预非小细胞肺癌的治疗与研究进展[J]. 辽宁中医杂志, 2026, 53(3): 211-216.
[46] 马定财, 王哲, 王毛毛, 等. 黄芪及活性成分治疗肺癌的研究进展[J]. 中国中药杂志, 2024, 49(2): 294-303.
[47] 段海婧, 宁艳梅, 吴国泰, 等. 非小细胞肺癌中医证型及用药规律的网络构建及可视化分析[J]. 中药药理与临床, 2023, 39(10): 87-92.
[48] 贺佐梅, 曾普华, 郜文辉, 等. 7435份非小细胞肺癌病案中医证候分布频数及关联分析[J]. 中医药导报, 2019, 25(16): 40-44.
[49] 张鹏飞, 张惠娟, 梁建庆, 等. 基于“扶正祛邪”理论探讨中医药治疗非小细胞肺癌的规律及机制[J].中国实验方剂学杂志, 2025, 31(24): 228-237.
[50] QI XJ, GUO ZH, CHEN QY, et al. A data mining-based analysis of core herbs on different patterns (Zheng) of non-small cell lung cancer[J]. Evid Based Complement Alternat Med, 2021, 2021: 3621677.
[51] 赵莹莹, 卢子遇, 李生龙, 等. 基于免疫疗法探讨中医药治疗非小细胞肺癌的研究进展[J]. 中国中药杂志, 2025, 50(16): 4415-4424.
[52] 蒋华, 杨文笑, 石振鹏, 等. “金水相生”视域下探析“益气养精”法论治非小细胞肺癌EGFR-TKIs获得性耐药[J]. 中华中医药杂志, 2025, 40(5): 2409-2412.
[53] 郑佳彬, 袁嘉萌, 刘益华, 等. 中医药联合化疗治疗晚期非小细胞肺癌临床疗效的研究进展[J]. 中华中医药杂志, 2018, 33(11): 5026-5030.
[54] 王选阳, 高原, 唐进法, 等. 黄芪及其药对研究进展[J]. 中华中医药学刊, 2025, 43(3): 155-160.
[55] MCCULLOCH M, SEE C, SHU XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials[J]. J Clin Oncol, 2006, 24(3): 419-430.
[56] 陆怡铭, 赵天成, 谢梓沄, 等. 黄芪及其活性成分抑制非小细胞肺癌研究进展[J]. 中药材, 2025(6): 1596-1604.
[57] WANG SF, WANG Q, JIAO LJ, et al. Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis[J]. Curr Oncol, 2016, 23(3): e188-95.
[58] WU CY, KE Y, ZENG YF, et al. Anticancer activity of Astragalus polysaccharide in human non-small cell lung cancer cells[J]. Cancer Cell Int, 2017, 17: 115.
[59] JIA LW, LV DY, ZHANG S, et al. Astragaloside IV inhibits the progression of non-small cell lung cancer through the Akt/GSK-3β/β-catenin pathway[J]. Oncol Res, 2019, 27(4): 503-508.
[60] 杨冰, 于桂红, 李明雨, 等. 基于“补气固表”探究黄芪黄酮组分抑制C57BL/6荷瘤小鼠肿瘤生长及免疫调节机制研究[J]. 中国中药杂志, 2019, 44(23): 5184-5190.
[61] 廖江龙, 范子祥, 孟秋月, 等. 丹参活性成分抗肿瘤分子机制研究进展[J]. 中草药, 2024, 55(18): 6402-6415.
[62] XIE J, LIU JH, LIU H, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line[J]. Acta Pharm Sin B, 2015, 5(6): 554-563.
[63] 陶丽, 王生, 赵杨, 等. 丹参素对非小细胞肺癌A549细胞内氧化还原状态及相关核转录因子的影响[J]. 中国中药杂志, 2012, 37(9): 1265-1268.
[64] 李淑莹, 侯雪楠, 侯宇鑫, 等. 丹参活性成分对Lewis肺癌细胞增殖迁移的作用及机制[J]. 中药新药与临床药理, 2025, 36(7): 1084-1093.
[65] 国丽茹, 李彦青, 王澜涛, 等. 丹参多酚酸治疗非小细胞肺癌合并急性脑梗死临床观察[J]. 中华肿瘤防治杂志, 2020, 27(6): 470-474.
[66] LU TM, ZHOU LR, CHU Z, et al. Cordyceps sinensis relieves non-small cell lung cancer by inhibiting the MAPK pathway[J]. Chin Med, 2024, 19(1): 54.
[67] KANG LP, XU C, XU P, et al. Brazilin inhibits the proliferation of non-small cell lung cancer by regulating the STING/TBK1/IRF3 pathway[J]. J Cell Mol Med, 2025, 29(13): e70688.
[68] GUO QY, ZHAO MH, WANG QX, et al. Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis[J]. Biomed Pharmacother, 2024, 173: 116304.
[69] ZHAO Z, WANG Y, GONG Y, et al. Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer[J]. J Transl Med, 2022, 20(1): 525.
[70] ZOU J, YANG Y, YANG Y, et al. Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway[J]. Biomed Pharmacother, 2018, 108: 130-136.
[71] JIANG ZB, HE QH, KANG LP, et al. Rutecarpine suppresses non-small cell lung cancer progression through activating the STING pathway and elevating CD8⁺ T cells[J]. Chem Biol Drug Des, 2025, 105(2): e70070.
[72] YANG LH, LI JF, XU LY, et al. Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway[J]. Cancer Manag Res, 2019, 11: 1167-1176.
[73] WANG YX, LUO WN, SHEN SN, et al. Glaucocalyxin A induces autophagy-mediated ferroptosis by targeting PRDX1 and TXNRD1 proteins in non-small cell lung cancer[J]. Phytomedicine, 2025, 148: 157280.
[74] QIN Y, LIAN JN, CHEN X, et al. Exploring the molecular mechanism of Taohong Siwu decoction in the treatment of non-small-cell lung cancer based on network pharmacology and molecular docking[J]. J Pharm Pharmacol, 2025, 77(6): 805-821.
[75] LI JX, LI RZ, SUN A, et al. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling[J]. Pharmacol Res, 2021, 171: 105574.
[76] ZHANG W, DING ML, FENG YR, et al. Modulation of cellular metabolism and alleviation of bacterial dysbiosis by Aconiti Lateralis Radix Praeparata in non-small cell lung cancer treatment[J]. Phytomedicine, 2024, 126: 155099.
[77] ZHAO SY, WU JJ, TANG Q, et al. Chinese herbal medicine Xiaoji decoction inhibited growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1[J]. J Ethnopharmacol, 2016, 181: 172-181.
[78] LI H, TAN L, ZHANG JW, et al. Quercetin is the active component of Yang-Yin-Qing-Fei-Tang to induce apoptosis in non-small cell lung cancer[J]. Am J Chin Med, 2019, 47(4): 879-893.
[79] GAO TK, HU SP, JIANG M, et al. Combining network pharmacology and transcriptomics to validate and explore the efficacy and mechanism of Huayu Wan in treating non-small cell lung cancer[J]. J Ethnopharmacol, 2025, 347: 119724.
[80] SALEHI M, MOVAHEDPOUR A, TAYARANI A, et al. Therapeutic potentials of curcumin in the treatment of non-small-cell lung carcinoma[J]. Phytother Res, 2020, 34(10): 2557-2576.
[81] CHEN Y, CHEN C, ZHANG XJ, et al. Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects[J]. Acta Pharm Sin B, 2020, 10(6): 1106-1121.
[82] SANOJ RN, PIAO HY, CHOI G, et al. Curcumin in exfoliated layered double hydroxide nanoparticles: Pre-clinical evaluation as lung cancer nanomedicine[J]. Colloids Surf B Biointerfaces, 2023, 228: 113386.
[83] ZHANG TT, CHEN YM, GE YY, et al. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers[J]. Acta Pharm Sin B, 2018, 8(3): 440-448.
[84] RUDNIK LAC, FARAGO PV, MANFRON BUDEL J, et al. Co-loaded curcumin and methotrexate nanocapsules enhance cytotoxicity against non-small-cell lung cancer cells[J]. Molecules, 2020, 25(8): 1913.
[85] SU QJ, PAN JQ, WANG CX, et al. Curcumin and baicalin co-loaded nanoliposomes for synergistic treatment of non-small cell lung cancer[J]. Pharmaceutics, 2024, 16(8): 973.
[86] XU F, LI MH, QUE ZJ, et al. Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer[J]. J Mater Chem B, 2023, 11(15): 3453-3472.
[87] WANG JF, TIAN N, TIAN TH, et al. Low toxicity ginsenoside Rg1-carbon nanodots as a potential therapeutic agent for human non-small cell lung cancer[J]. Colloids Surf B Biointerfaces, 2025, 246: 114392.
[88] QIU C, XIA F, TU QC, et al. Multimodal lung cancer theranostics via manganese phosphate/quercetin particle[J]. Mol Cancer, 2025, 24(1): 43.
[89] 吴建龙, 侯丛哲, 郝金旺, 等. 蟾毒它灵对非小细胞肺癌的抗肿瘤活性与肾毒性研究[J]. 中国现代应用药学, 2026, 43(9): 1470-1479.
[90] 伍世恒, 朱晨. 中药活性成分纳米制剂抗肿瘤的研究进展[J]. 今日药学, 2025, 35(8): 634-640.
[91] 许帆, 刘瑶, 阙祖俊, 等. 基于“正虚伏毒”探索纳米技术在中医药防治肿瘤转移中的应用[J]. 世界中医药, 2024, 19(20): 3167-3173.
[92] 彭世立, 郭健敏, 段小群, 等. 纳米粒给药系统的评价方法及毒性研究进展[J]. 今日药学, 2025, 35(2): 136-139.
[93] 王楠, 赵明宇, 楚天云, 等. 姜黄素及其纳米制剂治疗关节炎的研究进展[J]. 中国医药导刊, 2024, 26(2): 155-159.

基金资助

河南省中医药科学研究专项课题资助项目(2022JDZX126,2021JDZY015);河南省中医药管理局资助项目(2019ZY1011);河南中医药大学研究生科研创新能力提升计划资助项目(2024KYCX049)